Sanofi Acquires Vicebio to Advance Non-mRNA Respiratory Vaccines
Sanofi takes a major leap in vaccine innovation with the $1.15 billion acquisition of Vicebio, gaining access to cutting-edge Molecular Clamp technology and a strong pipeline of non-mRNA respiratory vaccines.
With promising candidates like VXB-241 targeting RSV and hMPV, this move strengthens Sanofi’s global position in combination vaccines, especially for high-risk populations. It’s a bold step toward broader access, better efficacy, and long-term leadership in immunization science. 🌍🔬